TNF and congenital rubella syndrome: Because of the clinical availability of TNF-α inhibitors like infliximab, or soluble TNF-α receptor like etanercept, TNF-α blockade could be explored clinically to improve the GVT potential of ex vivo activated NK cells, but additional agents would likely need to be explored to better control CRS, like tocilizumab.